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endpoint was 6.5% in the BES arm vs 7.1% in the EES arm (pNS). Between the BES
and EES arm no significant differences were observed in cardiac death 0.5% vs 1.3%, MI
4.5% vs 5.4%, TVR 3.5% vs 2.7% and TLR 2.7% vs 2.2, respectively. Definite and
probable stent thrombosis rate was 0.74% in BES and 1.79% in EES (p0.25).
Conclusions: Despite high complexity of lesions in the LL subgroup, good clinical
outcomes and low rate of revascularization were observed at 12 months post-procedure
with both types of drug eluting stents. Stent thrombosis rate was relatively low despite
multiple overlapping stents. Our findings confirm the safety efficacy of both drug-eluting
stents for treatment of patients with long lesions in coronary arteries.
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Background: To investigate with coronary CT angiography the mid-term outcome of a
percutaneously implanted, bio-resorbable, coronary scaffolding device.
Methods: As part of the ABSORB trial (A Clinical Evaluation of the Bioabsorbable
Everolimus Eluting Coronary Stent System in the Treatment of de Novo Native Coronary
Artery Lesions) 71 patients underwent non-invasive coronary CT angiography 18 months
after implantation of an everolimus eluting, bio-resorbable scaffold (BVS 1.1, Abbott
Vascular, Santa Clara, CA) for treatment of obstructive coronary artery disease. Using
semi-automatic vessel extraction, cross-sectional lumen and vessel areas were measured
at 1-mm longitudinal intervals including 5 mm beyond the scaffold borders. Acquired
MSCT data was further processed for calculation of fractional flow reserve in another
independent corelab (Heart Flow, CA, USA).
Results: At 180 days there were no deaths, three non-Q-wave myocardial infarctions and
four ischemia driven target lesion revascularizations. CT angiographic image quality
allowed qualitative evaluation in 67 patients, and quantitative evaluation in 61 patients.
The mean lumen area within the scaffolded site was 5.1  1.4 mm2, compared to the
7.1-mm2 nominal cross-sectional scaffold area. The average minimal lumen area
measured 3.5  1.0 mm2, and the area stenosis was 23  22% (range -64.2 – 72.0%).
Significant coronary obstruction was qualitatively assessed in a single patient. The mean
plaque area (vessel minus lumen area) measured 8.9  3.4 mm2. Coronary lumen
enlargement up to 13.3 mm2 was observed in one other patient. The non-invasive
functional assessment (functional flow reserve according to MSCT) is ongoing and the
complete results will be presented at the time of meeting.
Conclusions: Noninvasive evaluation by cardiac CT demonstrated good angiographic
results 18 months after implantation of a bio-absorbable coronary scaffolding device. The
feasibility of non-invasive FFR will be presented at the time of meeting.
TCT-582
Eighteen Month Clinical and Imaging Results from the DESSOLVE I First-
in-Human Trial of the MiStent® SES with Absorbable Polymer
John Ormiston1, James Stewart2, Mark Webster2, Mathias Vrolix3,
Robert Whitbourn4, Dennis Donohoe5, Charlene Knape5, Alexandra Lansky6,
Hiram Bezerra7, Peter Fitzgerald8, David Kandzari9, William Wijns10
1Mercy Angiography Unit, Auckland, New Zealand, 2Auckland City Hospital,
Auckland, New Zealand, 3Hospital Oost-Limburg, Genk, Belgium, 4St Vincent’s
Hospital, Melbourne, Victoria, 5Micell Technologies, Durham, NC, 6Yale School of
Medicine, New Haven, USA, 7Case Western Reserve University, Cleveland, OH,
8Stanford University Medical Center, Stanford, California, 9Piedmont Heart
Institute, Atlanta, USA, 10Cardiovascular Center Aalst, Aalst, Belgium
Background: The MiStent SES (Micell Technologies, Durham, NC) is an investiga-
tional DES characterized by use of crystalline sirolimus and a fully absorbable polymer
on a thin strut (64um) cobalt-chromium stent. The stent coating is eliminated from the
stent in 45-60 days with full absorption of the polymer by 90 days. The DESSOLVE I FIH
clinical trial was designed to evaluate the initial and long-term efficacy and safety of the
MiStent SES in a defined group of patients.
Methods: The DESSOLVE I FIH clinical trial is a single-arm study conducted at 5
international sites. Thirty patients with discrete de novo lesions (2.5-3.5 mm vessel
diameter and 20 mm length) in native coronary arteries were implanted with a single
MiStent SES. The patients had a primary intervention at either of 4-months, 6-months or
8-months with a subsequent intervention at 18-months. Angiography and IVUS were used
to evaluate the amount of neointimal hyperplasia and stent apposition, and OCT for vessel
healing and stent coverage. Clinical events were assessed at 8-months, 12-months and
18-months.
Results: The initial 4-months, 6-month and 8-month evaluations demonstrated an in-stent
LLL of 0.01, 0.21 and 0.10 respectively as assessed by core laboratory quantitative
angiography. Imaging with OCT demonstrated thin, homogenous coverage with high
rates of stent strut coverage at 6 and 8 months, 93% and 96%, with a low rate of stent strut
malapposition. The IVUS findings supported minimal neointimal hyperplasia with a
neointimal volume index of 0.8mm3/mm at 8 months. Long-term clinical outcomes and
angiographic, OCT and IVUS analyses at 18-months will be presented.
Conclusions: The MiStent SES demonstrates sustained efficacy and safety through 18
months post-procedure.
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Background: To evaluate the safety and effectiveness of the Elixir DESyneTM BD
Novolimus Eluting Coronary Stent System (CSS) with a bioabsorbable polymer com-
pared to the Endeavor Zotarolimus Eluting Coronary Stent System through the assessment
of clinical, angiographic, and IVUS endpoints.
Methods: A total of 149 patients were randomized 3:1, either to the Elixir DESyne BD
Novolimus Eluting CSS loaded with 5mcg per mm of stent length of Novolimus, a
sirolimus metabolite, eluted via a bioabsorbable polylactide-based polymer, or to the
Endeavor Zotarolimus-eluting CSS loaded with 10mcg per mm of stent length of
Zotarolimus eluted via a durable phosphoryl choline polymer. All patients were analyzed
for the primary endpoint of in-stent late lumen loss (LLL) assessed by QCA at 6 months.
Moreover, all patients underwent evaluation for the secondary endpoints including the
Device-orientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly
attributable to a non-intervention vessel, and clinically-indicated target lesion revascular-
ization; clinically-indicated Target Vessel Revascularization (TVR), and stent thrombosis
at 1, 6, 9, and 12 months and annually through 5 years. Lesions were also evaluated for
angiographic endpoints at 6 months including: in-segment LLL, percent diameter stenosis,
minimal lumen diameter post-procedure and at 6 months, and angiographic binary
restenosis (ABR) (50%). A subset of patients underwent intravascular ultrasound
(IVUS) evaluation including percent (%) neointimal obstruction at 6 months.
Results: The study met the primary endpoint demonstrating both non-inferiority and
superiority of the DESyne BD compared to the control (0.120.15 vs 0.670.47,
p0.001), additionally, in-stent ABR was significantly lower for DESyne BD (0% vs
7.9%, p0.003). Excellent clinical results at 6 months were demonstrated for both
devices. Clinical results through 12 months and additional angiographic and IVUS results
will be presented.
Conclusions: The study met the primary endpoint demonstrating both non-inferiority
and superiority of the DESyne BD compared to the control. Clinical results through 12
months and complete angiographic and IVUS results will be presented.
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Background: The MiStent SES (Micell Technologies, Durham, NC) is an investiga-
tional drug-eluting stent (DES) developed to address unfavorable late-term outcomes such
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as stent thrombosis. These events are hypothesized to be associated in part with durable
polymers of current DES. The MiStent SES uses a unique combination of components, a
crystalline formulation of sirolimus and a fully absorbable polymer on a thin-strut, cobalt
chromium stent platform. The polymer coating is eliminated from the stent in 45-60 days
with complete absorption in 90 days. Sirolimus is simultaneously released into the
surrounding tissue as a controlled elution.
Methods: The DESSOLVE II clinical trial is a 2:1 randomized study conducted at 26
sites evaluating the MiStent SES for superiority in late lumen loss as compared to the
control stent, the Medtronic Endeavor Sprint (Santa Rosa, CA). Patients with discrete de
novo lesions (2.5-3.5 mm vessel diameter and27 mm length) in native coronary arteries
were acceptable for inclusion in the trial. A total of 183 patients were randomized into
either the MiStent SES or Endeavor Sprint and patients had follow-up at 30-days, 6, 9, and
12-months post-procedure. Angiography was conducted at 9-months with two subgroups:
38 patients imaged using optical coherence tomography (OCT) and 29 patients partici-
pated in endothelial function testing (EFT).
Results: The MiStent SES was superior to Endeavor for the primary endpoint analysis of
late lumen loss. The OCT revealed a mean of 2% uncovered struts with good suppression
on neointimal hyperplasia. EFT demonstrated an overall return of endothelial function
with no incidence of vasoconstriction in either the test or control group. Additional
secondary endpoint data will be presented.
Conclusions: The MiStent SES is an innovative drug eluting stent with sirolimus in a
fully absorbable polymer demonstrating a superior performance as compared to the
Endeavor Sprint DES. OCT shows stent coverage at 9-months with a return of endothelial
function.
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Background: The aim of this first in human study is to assess safety and performance of
the Passeo-18 Lux Paclitaxel releasing PTA balloon (DCB) versus the uncoated
Passeo-18 balloon catheter (POBA) for the treatment of stenosis and occlusion of
femoropopliteal arteries.
Methods: Between October 2010 and August 2011, 60 subjects presenting with stenosis
or occlusion of femoropopliteal arteries were consecutively enrolled in this international,
multicenter, randomized controlled trial under a 1:1 allocation. Primary endpoint of the
study is late lumen loss (LLL) at 6 months assessed by an independent corelab using
quantitative vascular angiography (QCA). Secondary endpoints are binary restenosis (BR)
at 6 months, target lesion revascularization, change in mean ankle brachial index and
Rutherford classification and major adverse events (MAEs) at 6 and 12 months.
Results: Thirty-four men (56.7%) were enrolled in 5 sites. Mean age was 70.710.1
(range 45-90) years. Half of the subjects were treated with the Paclitaxel releasing balloon
(study group) and the other half with the uncoated balloon catheter (control group). The
majority of subjects presented with hypertension (73.3%), followed by smoking (68.3%),
history of PAD (63.3%), hyperlipidemia (61.7%) and diabetes mellitus (33,3%). Almost
two thirds (56.7%) of the subjects were in Rutherford Class 3 and 26.7% were in Class
2. LLL at 6 months was significantly better with 0.50.7mm in the DCB group versus
1.01.0mm in the POBA group (p0.033). Three (11.5%) subjects presented with BR in
the DCB group versus 9 (34.6%) in the POBA group (p0.048). The overall MAE rate
is identical in both groups with 4 (15%) MAEs each. ABI improvement was the same in
both groups from baseline (0.70.2) to 6 months (0.90.2). Clinical outcome in
Rutherford Class was sligthly better in the DCB group with an improvement from
3.00.8 at baseline to 1.61.4 at 6 months versus 2.90.8 to 1.71.3 in the POBA
group.
Conclusions: Six month Results are consistent with previously published data and
confirm the safety and efficacy of DCB for the treatment of symptomatic femoropopliteal
disease. LLL and BR Results were significantly better in the DCB group compared with
POBA.
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Background: Previous studies of drug-eluting stent (DES) restenosis have shown that
the morphologic pattern of in-stent restenosis (ISR) was an important predictor of
outcomes after plain balloon angioplasty or repeat DES placement. However, there is no
data available on the relationship between the restenosis pattern and angiographical
outcomes after paclitaxel-eluting balloon (PEB) angioplasty.
Methods: From September 2008 to August 2011, 304 lesions were treated with PEB for
ISR lesions after DES implatation. All of the initial DES were implanted in de novo
lesions (Sirolimus-eluting stent: 156, Paclitaxel-eluting stent: 53, Zotarolimus-eluting
stent: 52, Everolimus-eluting stent: 31, Biolimus-eluting stent: 12). We divided these
lesions into two groups: focal lesions and nonfocal lesions, which were diffuse,
proliferative and total lesions. We investigated the angiographic restenosis pattern and the
restenosis rate at follow-up coronary angiography (CAG). Follow-up CAG was per-
formed at 6 months after procedure.
Results: The angiographical follow-up rate was 91.1% (277 lesions: 99 focal lesions, 178
nonfocal lesions). The binary restenosis rate was 18.2% in focal lesions and 29.2% in
nonfocal lesions (p0.04). The figure shows the restenosis patterns at baseline and
follow-up of the lesions which restenosed for the second time. The recurrent restenosis
pattern at follow-up remained the same in 64.3%, became worse in 7.1% and improved
in 28.6%.
Conclusions: After PEB angioplasty for DES ISR lesions, the morphologic pattern of
ISR is also an important predictor of the outcomes. Most of the recurrent ISR patterns are
the same or better than preprocedural ISR patterns.
Pattern at
baseline Types of change
Pattern at
follow-up
Focal 18 lesions Improved 0 30 lesions
Same 15 lesions
Worse 3 lesions
Diffuse 37 lesions Improved 14 lesions 27 lesions
Same 21 lesions
Worse 2 lesions
Proliferative 7 lesions Improved 1 lesions 7 lesions
Same 6 lesions
Worse 0
Total 8 lesions Improved 6 lesions 6 lesions
Same 2 lesions
Worse 0
TCT-587
Drug-Coated Balloon For De Novo Coronary Lesions: Results From The
Valentines II Trial
Ron Waksman1, Antonio Serra2, Alfredo Rodriguez3,
Rembert Pogge von Strandmann4, Stefanie Stahnke4, Rebecca Torguson5,
Joshua Loh6, Fazila Malik7
1Georgtown University, Washington, DC, 2Hospital de Sant Pau y Santa Creu,
Barcelona, Spain, 3Otamendi Hospital, Buenos Aires, Argentina, 4Eurocor GmbH,
Bonn, Germany, 5Washington Hospital center, washington, DC, 6Medstar
Washington Hospital Center, Washington, DC, 7National Heart Foundation
Hospital & Research Institute, Dhaka, Bangladesh
Background: Drug-coated balloons (DCB) have emerged as a potential alternative in
treating in-stent restenosis; however, their role in the treatment of de novo lesions is
unclear. This study aimed to evaluate the safety and efficacy of the second-generation
DIOR DCB as an adjunct to plain old balloon angioplasty (POBA) for the treatment of de
novo coronary lesions.
Methods: Valentines II was designed as a prospective, multicenter, multinational,
Web-based registry. Eligible patients with stable or unstable angina, and/or documented
ischemia on stress testing with de novo lesions of 50% stenosis were prospectively
enrolled. Patients underwent POBA followed by DCB. In cases of suboptimal angio-
graphic success (TIMI flow 3 and/or residual stenosis of 30%), additional bail-out
bare metal stenting (BMS) was left to the operator’s discretion. The primary endpoint was
6-9 months major adverse cardiac events (MACE: all cause death, myocardial infarction,
target vessel revascularization and vessel thrombosis). A subset of patients underwent
angiography follow-up.
Results: 109 lesions in 103 patients were treated. Mean age was 62.6  10.2 years;
79.6% were male. Lesion stenosis at baseline and post treatment was 83.3  9.5% and
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